Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets

Huang, Guofeng; Zhou, Zhongmin; Srinivasan, Rekha; Penn, Marc S.; Kottke‐Marchant, Kandice; Marchant, Roger; Gupta, Anirban Sen

doi:10.1016/j.biomaterials.2007.12.015

Cited by 124 publications

(96 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further studies demonstrated that cyclic arginine-glycine-aspartic-liposomes had even higher affinity for activated platelets than their linear counterparts [99,100]. In another study, Sialyl…”

Section: Other Approaches Include the Modification Of Liposomes With mentioning

confidence: 97%

Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems

Rolfe

Thomas³

et al. 2013

CPD

View full text Add to dashboard Cite

Section: Other Approaches Include the Modification Of Liposomes With mentioning

confidence: 97%

Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems

Rolfe

Thomas³

et al. 2013

CPD

View full text Add to dashboard Cite

“…The binding affinities of some of the RGD-containing derivatives for α v β 3 range from 3.2 to 100 nM. 85,86 The addition of specific amino acid residues to peptide sequence motifs, such as RGD, that induce binding to cell-attachment proteins, strongly enhances the binding affinity of this peptide. The injection of the modified peptides induced antigen-specific serum antibodies.…”

Section: Peptidesmentioning

confidence: 99%

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Toporkiewicz¹,

Meissner²,

Matusewicz³

et al. 2015

IJN

View full text Add to dashboard Cite

There are many problems directly correlated with the systemic administration of drugs and how they reach their target site. Targeting promises to be a hopeful strategy as an improved means of drug delivery, with reduced toxicity and minimal adverse side effects. Targeting exploits the high affinity of cell-surface-targeted ligands, either directly or as carriers for a drug, for specific retention and uptake by the targeted diseased cells. One of the most important parameters which should be taken into consideration in the selection of an appropriate ligand for targeting is the binding affinity ( K D ). In this review we focus on the importance of binding affinities of monoclonal antibodies, antibody derivatives, peptides, aptamers, DARPins, and small targeting molecules in the process of selection of the most suitable ligand for targeting of nanoparticles. In order to provide a critical comparison between these various options, we have also assessed each technology format across a range of parameters such as molecular size, immunogenicity, costs of production, clinical profiles, and examples of the level of selectivity and toxicity of each. Wherever possible, we have also assessed how incorporating such a targeted approach compares with, or is superior to, original treatments.

show abstract

“…24,25 The structure is identified by NME spectra, in Figure S1 and Figure S2. Figure 6 shows that, in vitro, 0.1 μM ingredient of AERL.…”

Section: Rosmarinic Acid Downregulates P-selectin Expressionmentioning

confidence: 99%

Aqueous extract of Rabdosia rubescens leaves: forming nanoparticles, targeting P-selectin, and inhibiting thrombosis

Wang¹,

Tang²,

Zhu³

et al. 2015

IJN

View full text Add to dashboard Cite

The hot water extract of Rabdosia rubescens was traditionally used as an antithrombotic medicine. To explore its antithrombotic utility and mechanism, we carried out a series of in vitro and in vivo assays in this study. In vitro platelet aggregation assay showed that the half maximal inhibitory concentration values of aqueous extract of R. rubescens leaves (AERL) inhibiting platelet aggregation induced by thrombin, arachidonic acid, adenosine diphosphate, and platelet-activating factor ranged from 0.12 mg/mL to 1.43 mg/mL. The minimal effective oral dose of AERL inhibiting the rats from forming thrombus was 25 mg/kg. Both in vitro and in vivo actions were correlated with AERL concentration-dependently inhibiting sP-selectin release. In water, AERL formed nanoparticles, and their size depended on the concentration. Docking the five nucleotides, 21 phenolic acids, and four diterpenoids identified by high-performance liquid chromatography–photodiode array detector/(−)electrospray ionization-tandem mass spectrometry analysis into the active site of P-selectin, rosmarinic acid was predicted to be the antithrombotic ingredient of AERL. In flow cytometry analysis, 1 μM of rosmarinic acid effectively inhibited sP-selectin release in arachidonic acid-activated platelets. In a rat model, 5 mg/kg of oral rosmarinic acid effectively inhibited thrombosis.

show abstract

Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets

Cited by 124 publications

References 31 publications

Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems

Restenosis Treatments Using Nanoparticle-based Drug Delivery Systems

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

Aqueous extract of Rabdosia rubescens leaves: forming nanoparticles, targeting P-selectin, and inhibiting thrombosis

Contact Info

Product

Resources

About